Payment & Shipping Terms | Supply Capacity |
Payment Terms: | T/T, WU | Production Capacity: | 500kg/year |
Min. Order: | 1 Gram | Packing: | according to the customer's requirements |
Means of Transport: | Ocean, Air, Land | Delivery Date: | 7 days |
Finasteride
CAS: 98319-26-7
Item | Index |
Molecular formula | C23H36N2O2 |
Molecular weight | 372.54 |
Specification | CP/USP/EP |
Appearance | White or off-white crystalline solid |
Melting point | 253 °C |
Solubility | DMSO: 32 mg/mL, soluble |
Storage Condition | Store at RT |
Medical uses Benign prostatic hyperplasia
Physicians use finasteride for the treatment of benign prostatic hyperplasia (BPH), informally known as an enlarged prostate. The FDA-approved dose is 5 mg once a day. Six months or more of treatment with finasteride may be required to determine the therapeutic results of treatment. If the drug is discontinued, any therapeutic benefits reverse within about 6–8 months. Finasteride may improve the symptoms associated with BPH such as difficulty urinating, getting up during the night to urinate, hesitation at the start of urination, and decreased urinary flow.
Off-label uses
Finasteride is sometimes used in hormone replacement therapy for male-to-female transsexuals in combination with a form of estrogen due to its antiandrogen properties. However, little clinical research of finasteride use for this purpose has been conducted and evidence of efficacy is limited. Indeed, finasteride is a substantially weaker antiandrogen in comparison to conventional antiandrogens like spironolactone and cyproterone acetate. Finasteride has also been found to mitigate the effects of withdrawal after chronic alcohol use.
